Medical criteria for Medicare Advantage Plans and Commercial Products will be revised for Radiofrequency Ablation (RFA) to treat an isolated peripheral non-small-cell lung cancer lesion and for RFA to treat malignant nonpulmonary tumor(s) metastatic to the lung.